Drug Trial Radar · NCT07404553
A Study Of SHR-1918 In Participants With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors
Last checked: Nov 19, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
126
Planned (sponsor's estimate)
Start
Apr 30, 2026
Primary completion
Jul 2028
Study completion Aug 2028
Sponsor
- Lead sponsor
- Beijing Suncadia Pharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Feb 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the efficacy and safety of SHR-1918 in patients with hypercholesterolemia with inadequate lipid control on statins plus PCSK9 inhibitors. The efficacy and safety of SHR-1918 will be evaluated after 12-weeks and 24-weeks treatment.
Conditions
- Hypercholesterolemia
Interventions
SHR-1918 InjectionDrug
SHR-1918 injection.
SHR-1918 Injection PlaceboDrug
SHR-1918 injection placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change in low density lipoprotein cholesterol (LDL-C) levels at Week 12 relative to baseline.Time frame: At 12 weeks of treatment.
- Percentage change in low density lipoprotein cholesterol (LDL-C) levels at Week 24 relative to baseline.Time frame: At 24 weeks of treatment.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nanjing First Hospital
Nanjing, Jiangsu, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.